deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 4-arm NCT03872453

Acute Treatment Trial in Adult Subjects With Migraines

Phase II/III: Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial of BHV-3500 for the Acute Treatment of Migraine

Sponsor: Pfizer

Conditions Migraine
Interventions Intranasal Aptar Pharma Unit Dose System Zavegepant Zavegepant matching placebo
Updated 20 times since 2019 Last updated: Sep 14, 2023 Started: Mar 25, 2019 Primary completion: Oct 31, 2019 Completion: Nov 11, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03872453, this PHASE2/PHASE3 trial focuses on Migraine and remains completed. Sponsored by Pfizer, it has been updated 20 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Jan 2020 · 3 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Oct 2020 · 8 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshot~Apr 2022 – ~Sep 2022 · 5 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Jan 2023 · 2 months · monthly snapshot~Jan 2023 – ~Oct 2023 · 9 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 7 months · monthly snapshot~Jan 2026 – present · 3 months · monthly snapshot

Change History

20 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  5. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

▶ Show 15 earlier versions

  1. Jan 2023 — Oct 2023 [monthly]

    Completed PHASE2_PHASE3

  2. Nov 2022 — Jan 2023 [monthly]

    Completed PHASE2_PHASE3

  3. Sep 2022 — Nov 2022 [monthly]

    Completed PHASE2_PHASE3

  4. Apr 2022 — Sep 2022 [monthly]

    Completed PHASE2_PHASE3

  5. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2_PHASE3

  6. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  7. Feb 2020 — Oct 2020 [monthly]

    Completed PHASE2_PHASE3

  8. Jan 2020 — Feb 2020 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

  9. Oct 2019 — Jan 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2_PHASE3

  11. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2_PHASE3

  12. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2_PHASE3

  13. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2_PHASE3

  14. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2_PHASE3

  15. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE2_PHASE3

    First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Amherst, United States , Ann Arbor, United States , Austin, United States , Bellevue, United States , Biloxi, United States , Boston, United States , Chalmette, United States , Charleston, United States , Charlotte, United States and 68 more locations